Congo Approves Experimental Ebola Treatments by Gilead- Mapp- Toyama Chemical and Regeneron
Shots:
- Congo approves experimental Ebola treatments including Remdesivir by Gilead Sciences; ZMapp by Mapp Pharmaceutical; Favipiravir by Toyama and Regn3450- Regn3471- Regn3479 by Regeneron Pharmaceuticals
- Health authorities has approved these experimental treatments- as the Ebola epidemic continues to spread
- Total number of death are 59 and confirmed cases to 75 since last month- with ~ 11-000 in West Africa from 2013-2016- 33 people in northwest
Ref: Reuters | Image: Gilead
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
